Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents.
miRNAs Participate in MS Pathological Processes and Its Therapeutic Response.
Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study.
Mediterranean diet adherence and risk of multiple sclerosis: a case-control study.
Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.
Lack of pathogenicity of immunodominant T and B cell determinants of the nicotinic acetylcholine receptor epsilon-chain.
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Major histocompatibility complex haplotype RT1av1 is associated with relapsing/remitting experimental autoimmune encephalomyelitis.
Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks.
Narcolepsy in midbrain structural lesion.
Severe drug-induced liver injury related to therapy with dimethyl fumarate.
Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.
Segmenting and Validating Brain Tissue Definitions in the Presence of Varying Tissue Contrast.
High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes.
Reduction of voltage-operated sodium currents by the anticonvulsant drug sulthiame.
Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.
Abnormal Glycogen Storage by Retinal Neurons in Diabetes.
Acoustic variation during passage reading for speakers with dysarthria and healthy controls.
Biological therapy and neurological manifestations. What do we know?
Dysmyelinated lower motor neurons retract and regenerate dysfunctional synaptic terminals.
Web-based physiotherapy for people moderately affected with Multiple Sclerosis; quantitative and qualitative data from a randomized, controlled pilot study.
A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons.
Control of T cell activation by vitamin D.
Peptide motif for the rat MHC class II molecule RT1.Da: similarities to the multiple sclerosis-associated HLA-DRB1*1501 molecule.
The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Pages
« first
‹ previous
…
690
691
692
693
694
695
696
697
698
…
next ›
last »